GlassScriptPhysician profile
Amani Jambhekar
NPI 1235574526
$3,016.02
in general payments reported to CMS, 2019-2025
40 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.83 · 2020: $23.46 · 2021: $242 · 2022: $199 · 2023: $528 · 2024: $1,237 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,532.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $358.25 | 2021-2025 | Spy-Phi System |
| Myriad Genetic Laboratories, INC. | $303.20 | 2021-2023 | Myrisk |
| Merit Medical Systems INC | $300.64 | 2022-2025 | Savi Scout |
| Novartis Pharmaceuticals Corporation | $257.37 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $217.84 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Exelixis INC. | $147.47 | 2024-2025 | Cabometyx |
| Sobi, INC | $146.24 | 2023-2025 | |
| Janssen Biotech, INC. | $135.32 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $130.54 | 2021-2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $110.13 | 2024-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Aroa Biosurgery Incorporated | $85.42 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $60.10 | 2024 | Monoferric |
| Incyte Corporation | $56.00 | 2022-2025 | Jakafi |
| Daiichi Sankyo INC. | $54.72 | 2024-2025 | Enhertu |
| Tempus Ai, INC | $41.24 | 2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amani Jambhekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.